Galenika

What Galenika does

Galenika AD Beograd is a Serbian pharmaceutical manufacturer founded in 1945, headquartered in Zemun, Belgrade, with 501–1,000 employees. The company operates two production facilities — a medicines factory and a solid pharmaceutical preparations factory — manufacturing more than 250 products spanning generic prescription medicines, OTC dietary supplements, cosmetic products (including the Pantenol line), and medical devices. Manufacturing is conducted under GMP, ISO, and HACCP quality standards, and the company claims nearly the entire assortment is the result of in-house development. Its core technology is described as a digitally managed and controlled production system, indicating modern industrial automation rather than advanced AI-driven processes.

The company operates as a wholly-owned subsidiary of Brazilian NC Group, acquired in 2017, which also controls EMS, the largest pharmaceutical company in Brazil and one of the largest in Latin America. Galenika functions as NC Group's primary operating entity for the Western Balkans and EU expansion strategy. In January 2026, Galenika completed the acquisition of Slovenian distributor Sanofarm, gaining owned distribution access in Slovenia and Croatia along with exclusive distribution rights for Italian manufacturers Pharmalife Research and ESI products in Slovenia and Pharmalife in Croatia. A further expansion into the wholesale OTC market in North Macedonia was announced in October 2025.

Galenika's commercial model is B2B pharmaceutical manufacturing and wholesale distribution, with products moving through wholesale networks and retail pharmacy chains across Serbia and the broader Balkans. Pricing is not publicly disclosed. Marketing combines a Serbian-language content blog, social channels (Facebook, Instagram, YouTube, LinkedIn), and B2B engagement via LinkedIn. The company generates revenue primarily from one-time sales of its manufactured and distributed pharmaceutical products; revenue figures are not publicly reported.

Name

Galenika

Legal name

Galenika AD Beograd

Website

https://galenika.rs

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Galenika is a Serbian generic pharmaceutical manufacturer producing 250+ products across two GMP-certified factories. Wholly owned by Brazil's NC Group since 2017, it serves wholesale and retail pharmacy channels in the Western Balkans and, via its 2026 Sanofarm acquisition, in Slovenia and Croatia.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Dietary supplements
• Medical devices
• Pharmaceutical distribution

Headquarters

HQ city

Zemun

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Sale of generic medicines, dietary supplements, cosmetic products, and medical devices manufactured in two factories - a medicines factory and a solid pharmaceutical preparations factory. Over 250 products in portfolio.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Galenika manufactures generic prescription medicines, over-the-counter (OTC) drugs, dietary supplements, cosmetic products, and medical devices at two production facilities in Serbia. The company sells its manufactured products through wholesale pharmaceutical distributors and pharmacy retailers across Serbia, the Balkans, and CIS markets.

Product overview

Galenika is a pharmaceutical company with nearly 80 years of history, operating as part of Brazilian NC Group since 2017. The company produces over 250 products across two manufacturing facilities, including a medicines factory and a solid pharmaceutical preparations factory. The product portfolio consists of generic prescription medicines, OTC products (dietary supplements, cosmetic products like Pantenol line, and mouthwash solutions like HIBIDEKS), and medical devices. Additionally, through its Sanofarm acquisition, Galenika holds exclusive distribution rights for Italian manufacturers Pharmalife Research and ESI products in Slovenia and Croatia. The company operates under GMP, ISO, and HACCP quality standards.

Differentiator

Problem solved

Functional benefit

Brands

• Pantenol: Galenika's brand for Panthenol products, including Pantenol B3HA cream-gel, Pantenol solution, and other dermatological/cosmetic preparations. The brand was featured in the 'Panthenol Pink October' breast cancer awareness campaign.

Products and services

• OLIGOVIT Mg Direct

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• SanofarmcoreChannel Partner/ Reseller/ Distributor · 29 January 2026Galenika acquired 100% ownership of Slovenian distributor Sanofarm to strengthen its presence in Slovenian and Croatian markets as part of its EU expansion strategy. The acquisition includes Sanofarm's portfolio of dietary supplements and phytotherapeutic products.
• Pharmalife ResearchcoreChannel Partner/ Reseller/ Distributor · 29 January 2026Through the Sanofarm acquisition, Galenika assumed exclusive distribution rights for Italian manufacturer Pharmalife Research products in Slovenia and the Pharmalife brand in Croatia.
• ESI (Italian manufacturer)coreChannel Partner/ Reseller/ Distributor · 29 January 2026Through the Sanofarm acquisition, Galenika assumed exclusive distribution rights for Italian manufacturer ESI products in Slovenia.
• NC GroupcoreOthersBrazil-based parent company of Galenika Beograd since 2017. NC Group encompasses EMS, the largest pharmaceutical company in Brazil and one of the largest in all of Latin America. NC Group acquired Galenika to expand into Western Balkans and EU markets.
• PFP (advisory firm)minorImplementation/ SI/ Consulting PartnerPFP acted as advisor to Galenika Beograd on the acquisition of Slovenian company Sanofarm, working in conjunction with Schoenherr law firm.
• Schoenherr (law firm)minorImplementation/ SI/ Consulting PartnerSchoenherr provided legal advisory services to Galenika Beograd on the cross-border acquisition of Slovenian distributor Sanofarm in the pharmaceutical distribution sector.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Krka: Krka is a Slovenian generic pharmaceutical manufacturer producing prescription drugs, OTC products, and animal health products across CEE and Western Balkans. Directly comparable to Galenika as a regional Central European generic manufacturer with similar product breadth, distribution model, and Western Balkan market exposure. Krka represents the regional scale competitor Galenika is benchmarking against.
• Hemofarm: Hemofarm is a Serbian pharmaceutical manufacturer producing generic medicines, OTC products, and medical devices, now part of STADA. It is the most direct domestic competitor to Galenika in the Serbian market, with overlapping product portfolios and similar distribution channels into the Western Balkans.
• Alkaloid: Alkaloid is a North Macedonian pharmaceutical company producing generic drugs, OTC products, cosmetics, and chemical products. It is a directly comparable regional manufacturer operating in adjacent Balkan markets with a similar product mix and Western Balkans distribution footprint to Galenika.

Broad incumbents

• Zentiva: Zentiva is a major European generic pharmaceutical manufacturer headquartered in Prague, producing prescription generics, OTC, and consumer health products across dozens of European markets. It is a broader European generic peer that competes with Galenika in tender markets and serves as the larger-scale player Galenika must compete against in EU expansion.
• STADA Arzneimittel: STADA is a leading European generic and consumer healthcare company with a broad portfolio of generics, OTC products, and specialty pharmaceuticals. It owns Hemofarm (Galenika's direct Serbian competitor) and serves as a broader European incumbent that Galenika competes against across Western Balkans and increasingly in Slovenia/Croatia.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a global footprint and broad product portfolio. It represents the global-scale generic incumbent that competes with Galenika on price and scale in tenders, and serves as the upper-bound competitive benchmark for the generic pharma industry.
• Sandoz (Novartis): Sandoz is one of the world's largest generic and biosimilar pharmaceutical companies, now spun off from Novartis. It operates across all major European markets and competes with Galenika in generic prescription pharmaceuticals and biosimilars across the Balkans and broader EU.
• Hikma Pharmaceuticals: Hikma is a multinational generic pharmaceutical company producing branded and non-branded generics, injectable products, and specialty pharmaceuticals across the US, MENA, and Europe. It serves as a broader incumbent comparable to Galenika in the generic and specialty pharmaceutical space with similar export-oriented business models.

Others

• EMS (NC Group): EMS is the largest pharmaceutical company in Brazil and one of the largest in Latin America, and a sister company under NC Group. It is directly relevant as the parent group platform whose products, capital, and commercial capabilities can be leveraged by Galenika in European expansion. EMS shares product categories (generics, OTC) with Galenika.

Regional players

• Polpharma Group: Polpharma is a leading Polish pharmaceutical manufacturer producing generics, OTC products, and active pharmaceutical ingredients across Central and Eastern Europe. It is a relevant regional peer that operates in adjacent CEE markets with comparable generic pharma product mix and regional export orientation to Galenika.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/c/galenika
• Facebookfacebook.com/GalenikaRS
• LinkedInlinkedin.com/company/galenika-a-d-belgrade
• Instagraminstagram.com/galenika.rs

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galenika